The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Climb Bio Inc CLYM
$11.66
▼ -1.93%
($-0.23)
🔥 High Short Interest
Open
$11.89
Prev Close
$11.89
Day Range
$11.53 – $11.92
52W Range
$1.54 – $18.33
Market Cap
$669.71M
Beta
0.01
EPS (TTM)
$-0.82
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-08-10 |
| Shares Out. | 57,260,000 |
| Website | climbbio.com/ ↗ |
| Phone | 18668572596 |
| Employees | 29 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$13.5M |
| Free Cash Flow | -$53.1M |
| Total Assets | $246.3M |
| Total Liabilities | $6.7M |
| Equity | $239.5M |
About Climb Bio Inc
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Climb Bio Inc is a publicly traded company under the ticker symbol CLYM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
21 analysts (2026-09-01)